|
WO2018028972A1
|
|
Method for manufacturing a dosage form by additive manufacturing, a dosage form and a device for manufacturing a dosage form
|
|
US2019152918A1
|
|
Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
|
|
EP3445742A1
|
|
Crystalline tapentadol phosphate
|
|
EP3429998A1
|
|
Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
|
|
WO2017108960A1
|
|
Method for producing monomethyl fumarate compounds
|
|
WO2017108781A1
|
|
Abemaciclib form iv
|
|
EP3320898A1
|
|
Dosage form comprising a carrier structure and method for manufacturing the dosage form
|
|
WO2017076987A1
|
|
Composition comprising apremilast in amorphous form
|
|
WO2017046131A1
|
|
Processes for preparing solid state forms of dolutegravir sodium
|
|
EP3287467A1
|
|
Preparation of obeticholic acid comprising continuous flow process steps
|
|
WO2017029408A1
|
|
Solid state forms of sofosbuvir
|
|
EP3543235A1
|
|
Crystalline form and acetic acid adduct of palbociclib
|
|
WO2017012770A1
|
|
Acid addition salts of filgotinib
|
|
WO2017012773A1
|
|
Solid forms of filgotinib free base
|
|
WO2017012771A1
|
|
Crystalline filgotinib sulfonic acid addition salts
|
|
EP3248594A1
|
|
Tablet for multiple oral applications
|
|
EP3228306A1
|
|
Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
|
|
WO2016156330A1
|
|
Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
|
|
EP3277688A1
|
|
Co-crystals of ibrutinib
|
|
EP3253374A1
|
|
Composition comprising cebranopadol in a dissolved form
|
